Seattle Genetics, Inc. (SGEN) To Present Clinical Data From Broad Adcetris® (Brentuximab Vedotin) Development Program And Novel Antibody-Drug Conjugate (ADC) SGN-CD19A At American Society of Hematology 2013
11/11/2013 11:20:30 AM
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, Louisiana, December 7-10, 2013, highlighting the following:
•Clinical data for ADCETRIS (brentuximab vedotin) in CD30-positive lymphomas, including Hodgkin lymphoma (HL), mature T-cell lymphoma (MTCL), cutaneous T-cell lymphoma (CTCL) and diffuse B-cell lymphoma (DLBCL);
Help employers find you! Check out all the jobs and post your resume.
comments powered by